development of SC-related manuscripts, models, standards and other guidance materials (collectively, "Guidance"); (b) provide a venue for reviewing, developing, maintaining and supporting the Guidance; (c) promote the Guidance worldwide; (d) provide for testing and conformity assessment of implementations in order to ensure and/ or facilitate compliance with Guidance; (e) operate a branding program based upon distinctive trademarks to create high customer awareness of, demand for, and confidence in the Guidance, and products or services designed in compliance therewith; and (f) undertake such other activities as may from time to time be appropriate to further the purposes and achieve the goals set forth above.

Membership in Subcutaneous Drug Development & Delivery Consortium, Inc. remains open and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership.

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2020–26626 Filed 12–2–20; 8:45 am] BILLING CODE 4410–11–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-750]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: Janssen Pharmaceuticals Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 1, 2021. Such persons may also file a written request for a hearing on the application on or before February 1, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. **SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on November 11, 2020, Janssen Pharmaceuticals Inc., 1440 Olympic Drive, Athens, Georgia, 30601–1645, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methylphenidate Hydromorphone Hydrocodone Oripavine Thebaine Tapentadol	1724 9150 9193 9330 9333 9780	

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

William T. McDermott,

Assistant Administrator. [FR Doc. 2020–26651 Filed 12–2–20; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Federal Bureau of Investigation

[OMB Number 1110-0051]

Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection; Final Disposition Report (R–84), With Supplemental Questions R–84(a), R– 84(b), R–84(c), R–84(d), R–84(e), R– 84(f), R–84(g), R–84(h), R–84(i), and R– 84(j)

AGENCY: Criminal Justice Information Services Division, Federal Bureau of Investigation, Department of Justice. **ACTION:** 30-day notice.

SUMMARY: The Criminal Justice Information Services (CJIS) Division, Federal Bureau of Investigation (FBI), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. **DATES:** Comments are encouraged and will be accepted for an additional 30 days until January 4, 2021.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting

"Currently under 30-day Review—Open for Public Comments" or by using the search function.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- --Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
 - -Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the
- methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and
- -Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Overview of This Information Collection

(1) *Type of Information Collection:* Revision of a currently approved collection.

(2) *Title of the Form/Collection:* Final Disposition Report.

(3) Agency form number, if any, and the applicable component of the Department sponsoring the collection:

Agency form number: R-84, with supplemental questions R-84(a), R-84(b), R-84(c), R-84(d), R-84(e), R-84(f), R-84(g), R-84(h), R-84(i), and R-84(j).

Sponsoring component: Department of Justice, Criminal Justice Information Services Division.

(4) Affected public who will be asked or required to respond, as well as a brief abstract: *Primary:* City, county, state, federal and tribal law enforcement agencies. This collection is needed to report completion of an arrest event. Acceptable data is stored as part of the Next Generation Identification (NGI) system of the FBI.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that 75,605 respondents will complete each form within approximately 5 minutes.